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Seven of eight recent United States
studies on cancer survival found a signifi-
cant survival disadvantage with low socio-
economic status (SES).'-8 Cumulative
survival rates among patients of relatively
high SES were found to be approximately
50% greater than those of their lower-
status counterparts (mean odds ratio
[OR] = 1.50, crudely averaged across
studies and cancer sites). A similar associa-
tion between SES and cancer survival,
though of attenuated magnitude (mean
OR = 1.20), has also been observed in
recent studies carried out in continental
European9-15 and Nordic'1620 countries, as
well as Australia.21 This association has
been consistently observed for many of
the most common cancer sites not only
across countries, but also across different
measures of SES (individual and ecologi-
cal; education-, occupation-, housing-,
and income-based) and study designs
(population- and hospital-based; observa-
tional and analytic). Also, recent US
studies on race and cancer survival have
provided further, albeit more indirect,
evidence for such an association.223
Cumulative survival among Blacks was
found to be approximately 40% lower
than that of Whites (mean OR = 1.40);
however, the summary odds ratio dimin-
ished to 1.06 after adjustment for socioeco-
nomic factors, a point-estimate the com-
bined probability of which did not even
reach a minimally significant P < .05.2
This body of evidence seems to
implicate systemic environmental factors,
rather than individual ones, as explana-
tions for cancer survival differentials by
SES. For example, the US studies of
cancer survival by race with socioeco-
nomic adjustment imply that most
(1 - .061.40 = 85%) of the between-race
differential is probably accounted for by
prognostic (size of tumor or stage of
disease at diagnosis; delay until medical
consultation, type of insurance, relation-
ship with primary care physician, cancer
screening experience) and treatment (time-
liness, type, and intensity) factors. Biologi-
cal factors (degrees of tumor differentia-
tion, histology, hormone receptor status)
accounted for little or none of the
difference. The above between-country
meta-analytic comparison is also consis-
tent with the systemic environmental
inference. Health care system differences,
such as the greater representation of
universal single-payer systems in the
Nordic and other European countries,
may parsimoniously account for the greatly
diminished associations between SES and
cancer survival found in these countries as
compared with the United States. It ought
to be recalled, though, that this inference
is based on review-generated data; none
of the reviewed studies actually compared
the survival experience of two or more
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countries in any controlled manner. The
present study does so.
We are aware of only one previous
study-a US General Accounting Office
(GAO) study-that has compared the
cancer survival experience of a US
sample and a sample from another coun-
try.33 It compared Canada and the United
States on lung, breast, and colon cancer
and Hodgkin's disease survival. Five-year
survival rate ratios indicative of a small
advantage were observed for lung (1.05,
Canada advantage) and breast (1.04, US
advantage) cancer, while colon cancer and
Hodgkin's disease comparisons were sta-
tistically nonsignificant. Such cancer sur-
vival similarity between these two devel-
oped countries-arguably very similar in
many sociodemographic respects, but
dissimilar in the manner in which health
care resources are distributed-is counter
to the present study's hypothesis. In light
of the consistent literature on SES and
cancer survival, the GAO study findings
seem counterintuitive; one would expect
significant benefits to be observed among
Canadians, who enjoy universal access to
health care. The GAO study did not
include any measure of SES, and so could
not observe any modification of between-
country survival differences by SES. We
hypothesized such an interaction, specifi-
cally, that relatively poor Canadians would
enjoy advantaged cancer survival over
their similarly poor US counterparts.
Methods
Cancer cases arose from the popula-
tions of greater metropolitan Toronto,
Ontario (3.5 million in 1991; Toronto,
York, and Peel regions), and Detroit, Mich
(3.9 million in 1990; Wayne, Oakland,
and Macomb counties).34'35 Both cities are
on or very near to the Canadian-US
border, only 200 miles apart. They are
also both located on the Great Lakes
(Toronto on Lake Ontario and Detroit on
Lakes Erie and Huron via the Detroit
River) and are exposed to the same
general prevailing wind-driven weather
pattems.
The data sources were the Ontario
Cancer Registry (Toronto data) and the
National Cancer Institute's Surveillance
Epidemiology and End Results (SEER)
program (Detroit data). Definitions of the
study cohorts were constrained by the
following: 1986 was the first year in
which the Ontario Cancer Registry coded
most cases by residence (mandated hospi-
tal reporting was initiated), and cohort
terminations or dates of last follow-up for
American Journal of Public Health 1157July 1997, Vol. 87, No. 7
TABLE 1-Continued
Cancer Site 1-Year Survival 5-Year Survival
(ICD-9 Code) and
Income Group na SR SRRb (95% CI)C nd SR SRRb (95% CI)C
Men
Lung-bronchus (162)
High
Middle
Low
Prostate (185)
High
Middle
Low
Colon (153)
High
Middle
Low
Bladder (188)
High
Middle
Low
Rectum (154)
High
Middle
Low
Non-Hodgkin's
lymphoma (202)
High
Middle
Low
Stomach (151)
High
Middle
Low
Oral (1 41-1 49)
High
Middle
Low
Pancreas (157)
High
Middle
Low
Kidney (189)
High
Middle
Low
Brain-CNS (191 -192)
High
Middle
Low
1563 .368 1.00 622 .111 1.00
...
2402 .359 0.98 (0.91, 1.05) 1029 .142 1.28 (0.98,1.67)
2835 .354 0.96 (0.88, 1.05) 1251 .132 1.19 (0.91, 1.55)
2044 .903 1.00 ..
2713 .906 1.00 (0.98,1.02)
2410 .892 0.99 (0.97,1.01)
929 .771 1.00
1294 .761 0.99 (0.95,1.03)
1234 .750 0.97 (0.92, 1.02)
638 .872 1.00
872 .880 1.01 (0.97, 1.05)
864 .885 1.01 (0.99,1.03)
407 .798 1.00
594 .778 0.97 (0.90, 1.05)
614 .769 0.96 (0.89,1.03)
390 .690 1.00 ..
499 .659 0.96 (0.88,1.04)
611 .572 0.83 (0.75, 0.91)
335 .426 1.00 ...
462 .435 1.02 (0.86,1.21)
634 .440 1.03 (0.89,1.19)
226 .805 1.00
408 .798 0.99 (0.88,1.11)
528 .740 0.92 (0.84,1.00)
212 .175 1.00 ...
348 .184 1.05 (0.77,1.44)
359 .180 1.03 (0.77,1.38)
336 .732 1.00 ...
438 .790 1.08 (1.00,1.17)
467 .728 0.99 (0.86,1.14)
210 .472 1.00
285 .416 0.88 (0.71, 1.09)
269 .416 0.88 (0.71, 1.09)
636 .585 1.00
...897 .559 0.96 (0.89,1.04)
857 .546 0.93 (0.85,1.02)
362 .485 1.00
...
532 .450 0.93 (0.82,1.06)
547 .471 0.97 (0.85,1.11)
308 .643 1.00 ...
428 .659 1.02 (0.94,1.11)
414 .598 0.93 (0.83,1.05)
153 .472 1.00
226 .353 0.75 (0.58, 0.96)
267 .423 0.90 (0.72,1.12)
139 .438 1.00
...
208 .430 0.98 (0.80,1.19)
210 .363 0.83 (0.64,1.07)
119 .150 1.00 ...
167 .157 1.05 (0.40,2.73)
281 .195 1.30 (1.10,1.54)
85 .502 1.00
...
158 .514 1.02 (0.69,1.50)
236 .452 0.90 (0.70, 1.15)
86 .035 1.00
...
136 .046 1.31 (0.28, 6.02)
165 .078 2.23 (0.70, 7.08)
127 .537 1.00 ...
173 .567 1.06 (0.86,1.31)
183 .522 0.97 (0.69, 1.33)
88 .211 1.00
...
128 .181 0.86 (0.55, 1.34)
111 .262 1.24 (0.70, 2.20)
Note. ICD-9 = Intemational Classification of Diseases, 9th revision; n = number of cumulative
incident cancer cases; SR = cumulative survival rate; SRR = survival rate ratio; Cl =
confidence interval; CNS = central nervous system.
aCases diagnosed between 1986 and 1992.
bA survival rate ratio of 1.00 is the baseline.
CConfidence intervals are based on the Mantel-Haenszel chi-squared test.
dCases diagnosed between 1986 and 1988.
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the Toronto and Detroit cases were
December 31, 1993 and 1991, respec-
tively.36 So the Toronto cohort for 1-year
survival analysis was based on cumulative
incident cases diagnosed from 1986
through 1992, and that for the 5-year
survival analysis was based on cases
diagnosed from 1986 through 1988; both
were followed until December 1993. The
Detroit cohort was initiated in 1984 and
followed until December of 1991. All
primary, malignant cancers in the 15 most
common sites that occurred in adults (25
years of age or older) were included in the
analysis: 58202 cases in Toronto and
76055 in Detroit. The Ontario Cancer
Registry has been estimated to ascertain
more than 95% of the cancers that arise in
the province, which compares favorably
with the SEER-based Detroit registration
rate.37 This study's specific metropolitan
data sets were also found to be nearly
identical on other data quality indicators:
in the Toronto data set, 89.2% of the
cancers were microscopically confirmed
and 1.6% were enumerated on the basis of
death certificates only; for the Detroit data
set these figures were 90.6% and 1.4%,
respectively.
As is the case with nearly all cancer
registries, neither the Ontario nor the
SEER registry codes any socioeconomic
variables. Cancer cases were thus joined
by means of census tracts to socioeco-
nomic data collected by the 1991 and
1990 population censuses in Canada and
the United States, respectively. Such
geographic coding was based on each
person's residence at the time of diagno-
sis; these data were coded as postal codes
(converted to census tracts) in the Ontario
data set and as census tracts in the SEER
data set.38,39 The overall residential coding
rates for the two data sets were found to be
roughly comparable (Toronto = 94% and
Detroit = 98%).
Statistics Canada and the US Bureau
of the Census use conceptually similar
indices of economic impoverishment-
"low income" in Canada and "poverty"
threshold in the United States-which
facilitated this study's ecological between-
country comparison. Both are based on
annual household income from all sources,
adjusted for household size and tied to the
consumer price index. The Canadian
low-income cutoff is a more liberal
criterion, though, approximately equal to
200% of the US poverty threshold. For
example, in 1991 the Canadian low-
income threshold for a three-person house-
hold was $24 400 (Canadian dollars),
while in 1990 the US poverty threshold
for the same size household, adjusted for
the US dollar exchange rate, was
$11 700.40 These criteria were used to
divide the two cohorts into low, middle,
and high socioeconomic tertiles. The
analytic goal for the use of such census-
based socioeconomic measures was sim-
ply the aggregation of cancer cases into
relative tertiles, that is, low-, middle-, and
high-income areas within countries. The
1158 American Journal of Public Health
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1990 Toronto-Detroit comparison on in-
come status by tertile, in US dollars, was
as follows: high income (240 census
tracts, median income of $56 600, vs 354
tracts, $51 500), middle income (244,
$43 300, vs 355, $35 700), and low
income (244, $30 400, vs 356, $17 800).
The median Toronto census tract had 4843
residents, while 3661 people lived in the
average Detroit tract.
Cumulative survival rates were cor-
rected for competing causes of death by
excluding such outcome events. Only
deaths due to cancer were defined as valid
outcomes; deaths from other causes were
considered censored events.15'19 In fact,
the results of such censored analyses
differed little in most cases from analyses
performed with the uncorrected observed
survival rates, so the corrected findings
are reported alone in this paper. Survival
rates were directly age-adjusted, using
this study's combined Toronto-Detroit
population of cases by each specific
cancer site across the following age
categories: 25 through 44, 45 through 54,
55 through 64, 65 through 74, 75 years of
age or older. For within-country compari-
sons, the survival rate ratio (SRR) was the
ratio of low- to high-income tertile
survival rates; the survival rate ratio
indicates worse survival for the low-
income group if it is less than 1.00. Cancer
survival comparisons of Canadian and US
residents of low-income areas were then
accomplished so that the survival rate
ratio was greater than 1.00 if Toronto
residents were advantaged and less than
1.00 if Detroiters were. Confidence inter-
vals (95%) around survival rate ratios
were based on the Mantel-Haenszel chi-
squared test.41,42
Results
Within-Country Comparisons
In the Toronto metropolitan area, no
association was observed between SES-
low- vs high-income areas-and 1- or
5-year cancer survival for 12 of the 15
cancer sites studied (Table 1). The only
exceptions to this remarkably consistent
lack of association were for colon cancer
in women and non-Hodgkin's lymphoma
and oral cancer in men at 1-year follow-
up, and colon and bladder cancer in
women and stomach cancer in men at 5
years. Unexpectedly, an association in the
opposite direction-residents of lower-
income areas survived longer-was ob-
served among women with colon cancer,
and this is probably not a spurious finding,
TABLE 2-Association of Socioeconomic Status with Cancer Survival:
Detroit, Mich, 1991
Cancer Site 1-Year Survival 5-Year Survival
(ICD-9 Code) and
Income Group n SR SRRa (95% CI)b n SR SRRa (95% CI)b
Women
Lung-bronchus (162)
High
Middle
Low
Breast (174)
High
Middle
Low
Colon (153)
High
Middle
Low
Bladder (188)
High
Middle
Low
Rectum (154)
High
Middle
Low
Non-Hodgkin's
lymphoma (202)
High
Middle
Low
Corpus uterus (182)
High
Middle
Low
Stomach (151)
High
Middle
Low
Oral (141-149)
High
Middle
Low
Pancreas (157)
High
Middle
Low
Kidney (189)
High
Middle
Low
Ovary (183)
High
Middle
Low
Cervix uterus (1 80)C
High
Middle
Low
Brain-CNS (191-192)
High
Middle
Low
1528 .438 1.00 ... 336 .157 1.00 ...
1706 .396 0.90 (0.82, 0.98) 344 .104 0.66 (0.42,1.03)
2250 .341 0.78 (0.71, 0.85) 892 .095 0.61 (0.43, 0.86)
5071 .917 1.00 ... 1101 .671 1.00 ...
4470 .914 1.00 (0.99, 1.01) 1036 .632 0.94 (0.88,1.01)
4845 .876 0.95 (0.93, 0.97) 1850 .536 0.80 (0.75, 0.85)
1164 .742 1.00 ... 299 .439 1.00 ...
1296 .715 0.96 (0.91,1.01) 321 .460 1.05 (0.86,1.28)
1859 .699 0.94 (0.89, 0.99) 801 .360 0.82 (0.69, 0.98)
352 .800 1.00 ... 86 .616 1.00 ...
372 .788 0.98 (0.88,1.09) 97 .535 0.87 (0.67, 1.14)
385 .674 0.84 (0.75, 0.93) 171 .408 0.66 (0.50, 0.87)
466 .824 1.00 ... 117 .498 1.00 ...
497 .761 0.92 (0.85, 0.99) 144 .419 0.84 (0.62,1.13)
616 .763 0.89 (0.80, 0.99) 244 .398 0.80 (0.61, 1.05)
489 .666 1.00 ... 103 .447 1.00 ...
468 .661 0.99 (0.86,1.14) 111 .343 0.77 (0.53,1.12)
441 .620 0.93 (0.84,1.03) 170 .327 0.73 (0.54, 0.98)
996 .890 1.00 ... 236 .700 1.00
...927 .880 0.99 (0.96,1.02) 241 .590 0.84 (0.72, 0.98)
899 .793 0.89 (0.85, 0.92) 397 .583 0.83 (0.72, 0.95)
174 .376 1.00 ... 43 .114 1.00 ...
237 .410 1.09 (0.80,1.48) 62 .135 1.18 (0.44, 3.14)
388 .427 1.14 (0.87,1.49) 169 .116 1.02 (0.82,1.28)
201 .744 1.00 ... 52 .405 1.00
...208 .780 1.05 (0.93,1.18) 56 .520 1.28 (0.82, 2.01)
372 .697 0.94 (0.84, 1.05) 170 .400 0.99 (0.53,1.85)
340 .156 1.00 ... 103 .055 1.00 ...
343 .183 1.17 (0.85,1.62) 99 .033 0.60 (0.13,2.81)
578 .174 1.12 (0.82, 1.53) 250 .027 0.49 (0.16,1.55)
243 .695 1.00 ... 67 .423 1.00
...249 .717 1.03 (0.91, 1.16) 49 .556 1.31 (0.86, 1.99)
309 .636 0.91 (0.80, 1.04) 124 .360 0.85 (0.59, 1.24)
622 .692 1.00 ...
587 .669 0.97 (0.90,1.04)
611 .624 0.90 (0.82, 0.98)
243 .849 1.00
325 .823 0.97 (0.89,1.05)
633 .763 0.87 (0.78, 0.97)
202 .366 1.00
...187 .339 0.93 (0.72,1.20)
147 .282 0.77 (0.54, 1.10)
146 .317 1.00 ...
132 .271 0.85 (0.52, 1.40)
221 .294 0.93 (0.63,1.38)
60 .624 1.00
...93 .489 0.78 (0.57,1.07)
252 .437 0.70 (0.53, 0.92)
64 .147 1.00
...50 .088 0.60 (0.18, 2.05)
59 .122 0.83 (0.14, 2.07)
(Continued)
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TABLE 2-Continued
Cancer Site 1-Year Survival 5-Year Survival
(ICD-9 Code) and
Income Group n SR SRRa (95% CI)b n SR SRRa (95% CI)b
Men
Lung-bronchus (162)
High
Middle
Low
Prostate (185)
High
Middle
Low
Colon (153)
High
Middle
Low
Bladder (188)
High
Middle
Low
Rectum (154)
High
Middle
Low
Non-Hodgkin's
lymphoma (202)
High
Middle
Low
Stomach (151)
High
Middle
Low
Oral (141-149)
High
Middle
Low
Pancreas (157)
High
Middle
Low
Kidney (189)
High
Middle
Low
Brain-CNS (191-192)
High
Middle
Low
2426 .364 1.00 674 .114 1.00
...
2981 .339 0.93 (0.86,1.01) 767 .088 0.77 (0.55,1.08)
4729 .297 0.82 (0.76, 0.88) 2049 .067 0.59 (0.45, 0.78)
3386 .885 1.00 ... 615 .540 1.00
...3111 .844 0.95 (0.93, 0.97) 571 .457 0.85 (0.75, 0.96)
4487 .814 0.92 (0.90, 0.94) 1723 .450 0.83 (0.75, 0.92)
1291 .751 1.00 ...
1207 .716 0.95 (0.90,1.00)
1700 .675 0.90 (0.86, 0.94)
310 .437 1.00
...
285 .392 0.90 (0.73,1.10)
647 .341 0.78 (0.65, 0.94)
1099 .862 1.00 ... 245 .592 1.00 ...
964 .861 1.00 (0.98,1.02) 232 .540 0.91 (0.76,1.09)
844 .777 0.90 (0.86, 0.94) 352 .466 0.79 (0.67, 0.94)
656 .837 1.00 ... 193 .433 1.00
...626 .777 0.93 (0.88, 0.98) 156 .397 0.92 (0.72,1.17)
694 .738 0.88 (0.83, 0.93) 296 .375 0.87 (0.69,1.09)
544 .672 1.00 ... 125 .390 1.00 ...
491 .662 0.99 (0.92,1.07) 102 .326 0.84 (0.60,1.17)
475 .598 0.89 (0.80, 0.99) 190 .334 0.86 (0.65,1.15)
316 .401 1.00 ... 93 .145 1.00
...315 .398 0.99 (0.69,1.42) 73 .128 0.88 (0.25, 3.08)
659 .345 0.86 (0.71,1.05) 249 .113 0.80 (0.39,1.64)
405 .781
493 .731
930 .611
331 .146
297 .143
558 .129
1.00 ... 103 .404 1.00 ...
0.94 (0.87,1.01) 128 .292 0.72 (0.49,1.06)
0.78 (0.71, 0.85) 404 .248 0.61 (0.44, 0.85)
1.00 ... 81 .027 1.00 ...
0.98 (0.66,1.46) 97 .011 0.41 (0.03, 4.98)
0.88 (0.60,1.28) 251 .023 0.85 (0.25, 2.83)
365 .742 1.00 ... 92 .499 1.00 ...
364 .647 0.87 (0.78, 0.97) 100 .376 0.75 (0:51, 1.11)
420 .630 0.85 (0.77, 0.94) 171 .339 0.68 (0.48, 0.95)
243 .382 1.00
192 .333 0.87 (0.66,1.15)
161 .384 1.01 (0.65,1.56)
61 .124 1.00
...
50 .127 1.02 (0.55, 1.88)
59 .167 1.35 (0.55, 3.33)
Note. ICD-9 = Intemational Classification of Diseases, 9th revision; n = number of cumulative
incident cancer cases diagnosed between 1984 and 1990; SR = cumulative survival rate;
SRR = survival rate ratio; Cl = confidence interval; CNS = central nervous system.
aA survival rate ratio of 1.00 is the baseline.
bConfidence intervals are based on the Mantel-Haenszel chi-squared test.
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as it was observed at both 1-year
(SRR = 1.06) and 5-year follow-up
(SRR = 1.33). In the Detroit metropolitan
area, in clear contrast to the Canadian
findings, significant associations in the
hypothesized direction were observed for
12 of the 15 cancer sites studied 1 year
after diagnosis; 10 of 15 (12 of 15 if 90%
confidence intervals are used) remained
significant at 5-year follow-up (Table 2).
The significant 1-year survival differen-
tials, along with their tendency to increase
incrementally at 5-year follow-up (e.g.,
breast SRR = 0.95 1 year and 0.80 5
years after diagnosis; prostate SRR = 0.92
and 0.83, respectively) seem to under-
score the importance of both prognostic
and treatment-related factors.
Between-Country Comparisons
The two countries did not differ
significantly (at the 95% confidence level)
on survival for any cancer site in the
middle- or high-income groups. This
study's central analysis, the comparison of
Toronto and Detroit on cancer survival
among the poorest third of their respective
populations, is displayed in Table 3.
Significantly advantageous survival in
Toronto was observed for 13 of 15 cancer
sites across both periods of follow-up.
Rectal cancer and non-Hodgkin's lym-
phoma were the only nonsignificant excep-
tions among both women and men,
though between-country survival rate com-
parisons were also nonsignificant for
stomach and pancreas cancers among
women and brain cancer among men.
Each of the 5-year survival comparison
point-estimates was in the expected direc-
tion (SRRs > 1.00, Toronto advantage),
and for the five most common cancers
(lung, breast, prostate, colon, and bladder)
they may generally be characterized as
large differentials, indicative of a 20%
(prostate) to twofold (male lung) survival
advantage among Canadians who live in
relatively low-income areas compared
with their US counterparts.
Discussion
We studied the effect of socioeco-
nomic status (SES) on survival from the
15 most common types of cancer among
adult women and men in the populations
of Toronto, Ontario, and Detroit, Mich. In
within-country comparisons, Detroiters'
survival from cancer was significantly
(95% confidence interval) poorer among
people from lower-SES areas in 12 of 15
cancers. No such association was found
for 12 of 15 cancer sites among Toronto's
population. In the between-country analy-
sis, which compared cases arising from
Toronto and Detroit's low-income areas,
we found a significant Toronto survival
advantage for 13 of 15 cancer sites.
Furthermore, in both the within- and
between-country analyses, significant sur-
vival differentials were observed at 1-year
follow-up which increased for most sites
at 5-year follow-up, thus underscoring the
importance of both prognostic and treat-
ment-related factors.
1160 American Journal of Public Health
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These findings differ substantially
from those of the only other study that has
compared Canadian and US cancer sur-
vival.33 Whereas the GAO study found
little difference between Canada and the
United States in cancer survival, we
consistently observed large between-
country differences across most cancer
sites and periods of follow-up. The GAO
study tested only the main effect of
country on cancer survival; it did not
account for SES in any of its analyses. In
this study, we found that SES acts as an
effect modifier in such analyses, that is,
significant country X SES interactions
were observed. Canadian survival advan-
tages were observed only among the
ecologically defined poor; the two coun-
tries did not differ significantly on sur-
vival for any cancer site among middle- or
high-income groups.
Methodological Issues
Potential ecological fallacy. It is
important to note again that the SES
variable used in this cumulative survival
study was census based, so it is ecological
with respect to income measurement. Its
analytic goal was not, however, to assign
individuals a specific income based on
their census tract of residence as a proxy,
but rather, to assign them to one of three
broad SES classifications: residence in
relatively low-, middle-, or high-income
areas. The information bias that may
intrude because the socioeconomic expo-
sure variable is measured ecologically is
clearly far less potent when aggregating
cancer cases into socioeconomic tertiles,
as in this study, than when such ecological
measures are analytically employed as
more direct proxies for each individual's
SES.16,4346 Furthermore, the magnitude
of misclassification error that may affect
this analysis seems to compare favorably
with that routinely encountered in related
epidemiologic domains, and it is also
likely to be nondifferential.4748 An ana-
lytic addendum further refutes the notion
that this study's ecological measurement
of income potently confounds its findings.
When we used income quintiles we found
the following: (1) the nonsignificance of
Toronto's SES-survival associations was
maintained, (2) when we compared the
survival experience of Toronto's poorest
quintile (median income = $28 000) with
Detroit's second poorest (median in-
come = $26 300), the Toronto survival
advantage was maintained (e.g., breast
SRR = 1.21 and prostate SRR = 1.18,
both Ps < .05); and (3) such more abso-
lute measures of SES are substantially
correlated with this study's relative ones
in both the Canadian and US data sets
(r = .93 and .91, respectively, both
Ps < .05).
The ecological fallacy notwithstand-
ing, we believe it is important simply to
know that where people with cancer live,
specifically, whether they live in areas
where people of low SES tend to be
concentrated or in more affluent areas, is
highly associated with how long they live
in Detroit, but not in Toronto. This study's
contextual inferences are thus most rel-
evant to understanding community-level
phenomena such as systemic environmen-
tal factors that may differ between the
countries.49'50 One such cogent factor,
which parsimoniously fits with this study's
findings, is the prevailing health care
system. It may be assumed that Canada's
single-payer system provides more equiva-
lent access to ongoing preventive care and
medical consultation when symptoms
develop, as well as to the most effective
therapies once cancer is diagnosed, than
the insurance-driven US system. The
present study does not provide the means
to directly test this assumption, as the
Ontario Cancer Registry does not yet
routinely code prognostic and treatment-
related variables. A number of variables
such as stage of disease at the time of
diagnosis are, however, currently avail-
able on hard copy for more than 90% of
the Ontario cases. Funding is currently
being sought to incorporate them into the
Registry's electronic database, which
would allow a systematic replication of
this study that would account for such
factors.
Other potential alternative explana-
tions. In addition to the difference in their
health care systems, Toronto and Detroit
differ in another obvious and, as for the
present analysis, potentially confounding
way; recent censuses found that many
more Blacks live in Detroit's lowest-
income-tertile area (68%) than do in
Toronto's (5%). Ecological adjustment-
selection of a Detroit low-income area
American Journal of Public Health 1161
TABLE 3-Cancer Survival Rate Ratios for Residents of Lowest-income
Areas: Toronto, Ontario, vs Detroit, Mich
1-Year Survival 5-Year Survival
Cancer Site SRR (95% Cl)a SRR (95% Cl)a
Women
Lung-bronchus 1.19 (1.09,1.29) 1.58 (1.19, 2.10)
Breast 1.06 (1.04,1.08) 1.30 (1.23,1.38)
Colon 1.06 (1.01,1.12) 1.39 (1.20,1.61)
Bladder 1.19 (1.08, 1.31) 1.46 (1.15,1.85)
Rectum 1.06 (0.99,1.13) 1.09 (0.88,1.35)
Non-Hodgkin's lymphoma 1.07 (0.97,1.18) 1.27 (0.96,1.69)
Corpus uterus 1.18 (1.13,1.23) 1.34 (1.21,1.49)
Stomach 1.02 (0.87,1.20) 1.64 (0.93, 2.90)
Oral 1.16 (1.05, 1.28) 1.40 (1.08, 1.81)
Pancreas 1.22 (0.91, 1.63) 1.81 (0.55, 5.93)
Kidney 1.19 (1.07,1.33) 1.39 (1.04,1.86)
Ovary 1.12 (1.03,1.22) 1.38 (1.06,1.80)
Cervix uterus 1.17 (1.12,1.23) 1.48 (1.25,1.76)
Brain-CNS 1.70 (1.27, 2.28) 2.46 (1.12, 5.38)
Men
Lung-bronchus 1.19 (1.11, 1.27) 1.97 (1.58, 2.46)
Prostate 1.10 (1.08,1.13) 1.21 (1.11,1.32)
Colon 1.11 (1.06,1.16) 1.38 (1.19,1.60)
Bladder 1.14 (1.09,1.19) 1.28 (1.11,1.42)
Rectum 1.04 (0.98, 1.11) 1.13 (0.91, 1.40)
Non-Hodgkin's lymphoma 0.96 (0.87,1.06) 1.09 (0.83,1.43)
Stomach 1.28 (1.11, 1.48) 1.73 (1.12, 2.68)
Oral 1.21 (1.12, 1.31) 1.82 (1.45, 2.29)
Pancreas 1.40 (1.03, 1.91) 3.39 (1.32, 8.68)
Kidney 1.16 (1.03, 1.30) 1.54 (1.19, 1.99)
Brain-CNS 1.08 (0.86,1.35) 1.57 (0.80, 3.09)
Note. A survival rate ratio (SRR) greater than 1.00 indicates a survival advantage for Toronto.
Cl = confidence interval; CNS = central nervous system.
aConfidence intervals are based on the Mantel-Haenszel chi-squared test.
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with greatly diminished Black representa-
tion (20%, the low Black tertile of the
low-income tertile)-was necessary be-
cause the Ontario Cancer Registry does
not code racial group. This imperfect,
though substantial, adjustment for be-
tween-country racial group differences
did not result in any practical alteration of
findings. Among those predominantly
White people (80% in Detroit and 95% in
Toronto) who live in low-income areas,
area of residence remains highly associ-
ated with how long a person lives after
cancer is diagnosed in Detroit, but not in
Toronto.
A number of other factors, if they
were to differ significantly between
Toronto and Detroit low-income census
tracts, would confound this study's central
analysis: nutrition, physical activity, body
mass, smoking, and so on. No previous
study has specifically compared the low-
income areas of Toronto and Detroit on
these factors. However, prevalence stud-
ies of general Canadian and US popula-
tions suggest that they probably do not
explain this study's findings: recent Cana-
dian and US tobacco consumption was
found to be equivalent (2.48 kg per adult
in 1989), and prevalent differences in
other lifestyle-related factors (e.g., weight,
alcohol consumption) have been found to
be on the order of magnitude of only plus
or minus 2%. Finally, the possibility
that follow-up completion by SES ex-
plains this study's findings ought to be
addressed. Direct evidence on this score is
again lacking, but the fact that ascertain-
ment by death certificate only was not
significantly associated with SES among
cases arising in Toronto or Detroit makes
such confounding improbable.
Conclusions
This large cumulative survival study
of persons with the 15 most common
cancers in Canada and the United States
suggests that it is differences in the two
countries' health care systems that explain
the pronounced socioeconomic inequality
in survival observed in the United States
vs Canada's consistently egalitarian distri-
bution. If all Americans had equal access
to preventive and therapeutic health care
services, between-country differences such
as the observed cancer survival advantage
among Canadians would likely disappear.
A more detailed analysis of histologic,
prognostic, and treatment factor differ-
ences between individuals with cancer in
both countries would go a long way
toward strengthening (or refuting) the
validity of this inference. D
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